Real-world persistence of twice-weekly teriparatide and factors associated with the discontinuation in patients with osteoporosis.
Fujita R, Endo T, Takahata M, Haraya K, Suzuki H, Oda I, Kanayama M, Asano T, Shigenobu K, Iwata A, Yamada K, Takeuchi H, Ohura H, Yoneoka D, Iwasaki N.
Fujita R, et al. Among authors: ohura h.
J Bone Miner Metab. 2022 Sep;40(5):782-789. doi: 10.1007/s00774-022-01347-1. Epub 2022 Jun 27.
J Bone Miner Metab. 2022.
PMID: 35759143
Free PMC article.